Events & Ideas

Pinney Associates is honored to have been a part of the teams who worked tirelessly to achieve FDA approval of over-the-counter Opill, the first oral contraceptive to be made available without a prescription in the US (approved July 13, 2023). Popular Science’s 50 greatest innovations of 2023

December 3-6, 2023 | Tampa, FL Jack Henningfield will be attending. VIEW CONFERENCE Posters:No Indication of Abuse or Withdrawal Potential with Esmethadone (REL-1017): Results From Two Phase 3 Randomized Placebo-Controlled Trials in Patients With Major Depressive Disorder Nonclinical Studies of Abuse Potential With Dual Orexin Receptor Antagonists: Concordance With Real-World Use

October 19-20, 2023 | San Diego, CA Judy Ashworth and Ryan Lanier will be attending and participating in a panel session. VIEW CONFERENCE Panel Session:Overview of the Current Regulatory Landscape and Challenges in the Development of New Safer and Effective Analgesic Drugs

September 11-13, 2023 | London Joe Gitchell, Robyn Gougelet, Arielle Selya, and Floe Foxon will be attending and presenting. VIEW CONFERENCE Presentations:Poster #135: Updated Population-Level Counterfactual Trend Modelling to Examine the Relationship between Smoking Prevalence and E-Cigarette Use among US Adults and Adolescents Poster #158: What Substances are Adolescents Vaping? Estimating Nicotine-Specific and Marijuana-Specific Vaping… Read More

September 21-24, 2022 | Haarlem, Netherlands Judy Ashworth will be attending and participating in a panel discussion. Novel Compounds or Existing Molecules Panelists: David Nichols, Michelle Baker-Jones, Paul Stamets, Judy Ashworth Moderator: Matthew Baggott VIEW CONFERENCE WEBSITE

June 22-25, 2022 | Aspen, CO Joe Gitchell will be attending and is happy to talk to/meet up with other attendees. VIEW CONFERENCE WEBSITE

June 11-15, 2022 | MINNEAPOLIS, MN
Jack Henningfield, August Buchhalter, and Ryan Lanier will be attending CPDD.

MAY 23–24, 2022 | WASHINGTON, DC
Following a presentation of the results from a 2021 survey of key stakeholders which elicited expert opinions on best practices and metrics to assess the safety of psychedelic drugs within the context of a REMS, as well as the most effective structure for such programs (e.g., individual vs. shared REMS programs), panelists in this session will discuss the most relevant aspects for designing appropriate REMS programs for this new class of medicines.